Published in Hepatitis Weekly, November 21st, 2005
"To examine the benefits of steroid avoidance in adult living donor liver transplantation, we compared the clinical courses of nine recipients receiving basiliximab or daclizumab and 13 historical patients who received steroids," researchers in Japan report.
"The 1-year patient and graft survival and the incidence of acute cellular rejection were similar in both groups," according to S. Marubashi and colleagues, Osaka University.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.